Peer-reviewed veterinary case report
Safety and effects of aminocaproic acid in 122 dogs treated 2010-2012
By Davis, Megan & Bracker, Kiko·Published in Journal of the American Animal Hospital Association·2016·From the Department of Emergency/Critical Care·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Retrospective Study of 122 Dogs That Were Treated with the Antifibrinolytic Drug Aminocaproic Acid: 2010-2012.
- Species:
- dog
Plain-English summary
A group of 122 dogs received a medication called aminocaproic acid to help stop bleeding and reduce the need for blood transfusions. While three dogs had minor side effects from the drug, overall, it was well-tolerated, and there were no major issues. The study looked at different causes of bleeding, such as tumors or other health problems, but found no significant differences in how well the medication worked across these groups. Most dogs treated with aminocaproic acid did not need a blood transfusion, indicating that the treatment was effective in managing their bleeding.
People also search for: dog bleeding treatment · aminocaproic acid for dogs · dog blood transfusion alternatives
Abstract
Antifibrinolytic drugs are used to promote hemostasis and decrease the need for red blood cell transfusion. Medical records of 122 dogs that were prescribed either oral or intravenous aminocaproic acid between 2010 and 2012 were evaluated retrospectively. Of the 122 dogs, three experienced possible drug-related adverse effects. No significant differences were identified between dogs that experienced adverse effects and those that did not and the possible adverse effects noted were all minor. All dogs that received packed red blood cell transfusions were evaluated for correlations between baseline packed cell volume or dose of red blood cells and aminocaproic acid dose and no correlation was identified. Dogs that received aminocaproic acid as a treatment for active bleeding were divided by cause of hemorrhage into the following groups: neoplastic, non-neoplastic, and unknown. No significant differences in aminocaproic acid dose or the percentage of patients requiring a blood transfusion were identified between groups.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27008326/